Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
Education: Study
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 79 results found since Jan 2013.
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent
Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively
Patients in Study ... Biopharmaceuticals, Cardiology Amgen, Repatha, evolocumab, FOURIER trial
Source: HSMN NewsFeed - March 20, 2017 Category: Pharmaceuticals Source Type: news
New Study Shows Prevencios Simple Blood Test Determines Risk of Heart Attack, Stroke, or Cardiovascular Death
KIRKLAND, Wash.--(Healthcare Sales & Marketing Network)--Prevencio, Inc. today announces the presentation of data which demonstrate that a simple blood test is more accurate than commonly-used risk factors in determining whether a person will have a heart ... Diagnostics, Cardiology Prevencio, HART CVE, HART CAD
Source: HSMN NewsFeed - March 17, 2017 Category: Pharmaceuticals Source Type: news
Landmark Outcomes Study Shows That Repatha ® (Evolocumab) Decreases LDL-C To Unprecedented Low Levels And Reduces Risk Of Cardiovascular Events With No New Safety Issues
Repatha Significantly Reduces Risk of Hard Major Adverse Cardiovascular Events by 20 Percent
Risks of Heart Attack, Stroke and Coronary Revascularization Were Nominally Reduced by 27 Percent, 21 Percent and 22 Percent, Respectively
Patients in Study had History of Heart Attack, Stroke or Symptomatic Peripheral Arterial Disease and Were Treated With Optimized Statin Therapy
Amgen to Offer Innovative Refund Contracts in the U.S.
Detailed Results Simultaneously Published in the New England Journal of Medicine and Presented at the American College of Cardiology 66th Annual Scientific Session
THOUSAND OAKS, Calif.,...
Source: Amgen News Release - March 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Phase III COMPASS study with Bayer's rivaroxaban (Xarelto ®) shows overwhelming efficacy and meets primary endpoint early
Bayer AG and its cooperation partner Janssen Research & Development, LLC have announced that the Phase III trial COMPASS evaluating the efficacy and safety of rivaroxaban (Xarelto®) for the prevention of major adverse cardiac events (MACE) including cardiovascular death, myocardial infarction and stroke in patients with coronary artery disease (CAD) or peripheral artery disease (PAD) has met its primary endpoint ahead of time.
Source: World Pharma News - February 14, 2017 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Making Sense of Nutraceuticals in China
The Chinese nutraceutical market is considered the third largest in the world after the US and Japan, or the fourth largest if Europe is counted as a single market.Despite strong fundamentals and high rates of annual growth, though, the Chinese market remains some way from realizing its true potential. Its evolution is muddied by ambiguities around what nutraceuticals actually are and how they should be managed.The result has been polarization between over-zealous regulation of so-called health foods, and a grey market where products have skirted approval procedures through questionable positioning or by exploiting alterna...
Source: EyeForPharma - February 10, 2017 Category: Pharmaceuticals Authors: Marc Yates Source Type: news
Phase III COMPASS study with Bayer ’s Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early (for specialized target groups only)
Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke / Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient population
Source: Bayer Company News - February 8, 2017 Category: Pharmaceuticals Source Type: news
08.02.17: Not intended for U.S. and UK Media
Phase III COMPASS study with Bayer's Rivaroxaban in Patients with Coronary or Peripheral Artery Disease Shows Overwhelming Efficacy and Meets Primary Endpoint Early Coronary or peripheral artery disease patients carry significant risk of fatal or debilitating myocardial infarction and stroke / Rivaroxaban is the only non-vitamin K antagonist oral anticoagulant currently under assessment in this high risk patient populationmehr ...
Source: Bayer IR Newsfeed: Events - February 7, 2017 Category: Pharmaceuticals Source Type: news
Amgen announces Repatha ® (evolocumab) significantly reduced the risk of cardiovascular events in FOURIER outcomes study
Amgen (NASDAQ:AMGN) has announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and the key secondary composite endpoint (cardiovascular death, non-fatal MI or non-fatal stroke).
Source: World Pharma News - February 3, 2017 Category: Pharmaceuticals Tags: Featured Amgen Business and Industry Source Type: news
Amgen Announces Repatha ® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Landmark Repatha Cardiovascular Outcomes Study Meets Primary and Key Secondary Endpoint
Detailed Results to be Presented at ACC 66th Annual Scientific Session
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the FOURIER trial evaluating whether Repatha® (evolocumab) reduces the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina or coronary revascularization) and ...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Study Suggests Heart Patients May Need Fewer Blood Thinners
Researchers said a study involving reduced doses of Johnson& Johnson ’s anticoagulant Xarelto suggests it may be possible for patients with two types of heart disease to avoid the need for three different blood thinners to protect them from stroke and heart attack.
Source: WSJ.com: Health - November 15, 2016 Category: Pharmaceuticals Tags: PAID Source Type: news
'Mediterranean' diet linked to lower risk of heart attacks & strokes in heart patients
A "Mediterranean" diet, high in fruit, vegetables, fish and unrefined foods, is linked to a lower risk of heart attack and stroke in people who already have heart disease, according to a study of over 15,000 people in 39 countries around the world. The research also showed that eating greater amounts of healthy food was more important for these people than avoiding unhealthy foods, such as refined grains, sweets, desserts, sugared drinks and deep-fried food - a "Western" diet.
Source: World Pharma News - April 27, 2016 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Studies Show Testosterone Users May Face Heart Attack Risk; Attorneys...
Attorney handling testosterone lawsuits for heart attack and stroke allegations have updated their website at AndrogelTestosteroneLawsuitCenter.com; these testosterone attorneys provide no-cost case...(PRWeb December 03, 2014)Read the full story at http://www.prweb.com/releases/androgel-testosterone/heart-attack/prweb12367210.htm
Source: PRWeb: Medical Pharmaceuticals - December 4, 2014 Category: Pharmaceuticals Source Type: news
More Study Urged on Testosterone Drugs
A Food and Drug Administration panel recommended that makers of testosterone-replacement drugs study possible increased risks of heart attack and stroke from the hot-selling products.
Source: WSJ.com: Health - September 18, 2014 Category: Pharmaceuticals Tags: PAID Source Type: news
Diabetes Care “Bundle” Produces Better Health Outcomes, AJMC Study...
Geisinger Health System’s use of a diabetes care system among high-risk patients produced lower risks of myocardial infarction, stroke and retinopathy over a three-year period, according to a study in...(PRWeb June 27, 2014)Read the full story at http://www.prweb.com/releases/2014/06/prweb11979766.htm
Source: PRWeb: Medical Pharmaceuticals - June 27, 2014 Category: Pharmaceuticals Source Type: news
